Jan Skvarka
Director/Board Member at ZENTALIS PHARMACEUTICALS, INC.
Net worth: 764 030 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kimberly Blackwell | M | 55 | 4 years | |
| Cam Gallagher | M | 54 | 10 years | |
| David Johnson | M | 59 | 4 years | |
| Diana Hausman | M | 61 | 1 years | |
| Markus Warmuth | M | 53 | 4 years | |
| Adel Nada | M | - |
GentiBio, Inc.
 GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | - |
| Andrew Schiff | M | 58 | 4 years | |
| Sharon Townson | M | 49 | 4 years | |
| Meena Rao | M | - | 7 years | |
| Andrew Muratore | M | - | 3 years | |
| NATHANIEL BROOKS HORWITZ | M | - |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | 4 years |
| Mark Lackner | M | 56 | 2 years | |
| Nenad Grmusa | M | - |
DEM BioPharma, Inc.
 DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | 2 years |
| Alexander Mayweg | M | 49 | 6 years | |
| Enoch K. Kariuki | M | 42 | 3 years | |
| Deborah Baron | F | 55 | 3 years | |
| Karan Takhar | M | 32 | 7 years | |
| John Castle | M | 54 | 4 years | |
| Jennifer Champoux | F | - | 3 years | |
| Anthony Manning | M | 62 | 1 years | |
| John McCabe | M | 55 |
DEM BioPharma, Inc.
DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | 2 years |
| Ali Behbahani | M | 47 | 4 years | |
| Chandra Paul Leo | M | 55 | 4 years | |
| Christine Siu | F | 47 | 4 years | |
| Andrea Paul | F | 43 | 2 years | |
| Philip Nickson | M | 45 | 3 years | |
| Julia Deutsch | F | - | - | |
| Alexandra Roy | F | - | - | |
| Chuck Silberstein | M | - |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | 2 years |
| Filip Janku | M | 50 | 3 years | |
| Jane H. Buckner | M | - |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | - |
| Hadas Weinstein-Marom | M | - |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | - |
| David Rawlings | M | - |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | - |
| Dylan Morris | M | - |
DEM BioPharma, Inc.
DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | 2 years |
| Dimitris Voliotis | M | 61 | 4 years | |
| Owen Wallace | M | 55 | 3 years | |
| Daniel Janney | M | 58 |
DEM BioPharma, Inc.
DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | - |
| Gideon Gross | M | - |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | - |
| Michael Rapé | M | - | 4 years | |
| Kyle Rasbach | M | - | - | |
| Kimberly Freeman | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Melissa Epperly | F | 46 | 5 years | |
| Kevin Bunker | M | 52 | 9 years | |
| Robert L. Kirkman | M | 75 | 8 years | |
| Calvin Stiller | M | 83 | 8 years | |
| Robert A. Uger | M | 53 | 8 years | |
| James Parsons | M | 58 | 10 years | |
| Luke Beshar | M | 65 | 7 years | |
| Rosemary Harrison | M | 41 | 1 years | |
| Scott Myers | M | 57 | - | |
| Penka Petrova | M | 56 | 8 years | |
| Thomas Reynolds | M | 65 | 7 years | |
| Helena Tayton-Martin | M | 57 | 4 years | |
| Paul Walker | M | 49 | 1 years | |
| Michael G. Moore | M | - | 7 years | |
| Michael Kamarck | M | 73 | 1 years | |
| Paolo Pucci | M | 63 | 1 years | |
| Ajim Tamboli | M | 47 | 3 years | |
| Jullian Jones | M | - | - | |
| Catherine Mackey | M | 68 | - | |
| Abdelmalik Slassi | M | 62 | 3 years | |
| Ingmar Bruns | M | 49 | 1 years | |
| Brian Jahns | M | - | - | |
| Yaping Shou | M | - | 2 years | |
| Carrie Brownstein | M | 54 | 2 years | |
| Benjamin Looker | M | 42 | - | |
| Peter Huang | M | - | 7 years | |
| Iris Roth | M | 54 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 46 | 67.65% |
| Canada | 22 | 32.35% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jan Skvarka
- Personal Network
